Lifevantage Corp
LFVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000849146
In the last 90 days, Lifevantage Corp insiders filed 1 open-market purchase and 2 sales; 88 institutions reported holding it in 13F filings for Q2 2026, worth $36.9M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:12 AM ET
Revenue flow, FY2026
Where the revenue went in FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Aug 27, 2026 | Sep 4, 2025 | Aug 28, 2024 | Aug 28, 2023 | Aug 23, 2022 |
| Revenue | $182.6M | $228.5M | $200.2M | $213.4M | $206.4M |
| Cost of revenue | $41.0M | $44.9M | $41.4M | $43.4M | $38.1M |
| Gross profit | $141.6M | $183.7M | $158.7M | $170.0M | $168.3M |
| Operating expenses | $135.5M | $171.5M | $154.4M | $165.8M | $160.7M |
| Research and development | $1.00M | $1.40M | $700.0K | $600.0K | $700.0K |
| Selling, general and administrative | $58.4M | $69.2M | $68.5M | $71.1M | $63.4M |
| Operating income | $6.10M | $12.2M | $4.33M | $4.26M | $7.58M |
| Interest expense | – | – | -$430.0K | -$198.0K | $10.0K |
| Income tax | $994.0K | $2.44M | $1.41M | $1.46M | $1.57M |
| Net income | $5.07M | $9.80M | $2.94M | $2.54M | $3.12M |
| EPS, basic | $0.40 | $0.80 | $0.24 | $0.20 | $0.24 |
| EPS, diluted | $0.40 | $0.75 | $0.23 | $0.20 | $0.24 |
| Weighted shares, basic | 12.5M | 12.3M | 12.5M | 12.6M | 12.9M |
| Weighted shares, diluted | 12.7M | 13.0M | 13.0M | 12.6M | 13.1M |
| Margins and growth | |||||
| Gross margin | 77.6% | 80.4% | 79.3% | 79.7% | 81.5% |
| Operating margin | 3.3% | 5.3% | 2.2% | 2.0% | 3.7% |
| Net margin | 2.8% | 4.3% | 1.5% | 1.2% | 1.5% |
| Revenue growth, year over year | −20.1% | +14.2% | −6.2% | +3.4% | −6.3% |
| Net income growth, year over year | −48.3% | +233.8% | +15.6% | −18.6% | −75.8% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Aug 27, 2026 | Sep 4, 2025 | Aug 28, 2024 | Aug 28, 2023 | Aug 23, 2022 |
| Cash and equivalents | – | $20.2M | $16.9M | $21.6M | $20.2M |
| Accounts receivable | $2.99M | $3.29M | $2.95M | $1.61M | $3.34M |
| Inventory | $16.2M | $20.7M | $15.1M | $16.1M | $16.5M |
| Total current assets | $38.3M | $50.9M | $37.6M | $44.3M | $47.0M |
| Property, plant and equipment | $7.31M | $6.21M | $7.81M | $9.09M | $9.50M |
| Goodwill | $465.0K | – | – | – | – |
| Intangible assets | $3.06M | $245.0K | $323.0K | $455.0K | $587.0K |
| Total assets | $62.1M | $72.0M | $60.3M | $66.1M | $70.7M |
| Accounts payable | $5.16M | $4.60M | $5.85M | $3.50M | $7.46M |
| Total current liabilities | $20.2M | $27.2M | $22.3M | $19.6M | $25.7M |
| Total liabilities | $28.5M | $37.3M | $34.3M | $31.5M | $39.2M |
| Shareholders' equity | $33.6M | $34.6M | $26.0M | $34.6M | $31.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Aug 27, 2026 | Sep 4, 2025 | Aug 28, 2024 | Aug 28, 2023 | Aug 23, 2022 |
| Operating cash flow | $10.2M | $11.9M | $12.2M | $6.83M | $7.96M |
| Capital expenditures | $3.57M | $1.37M | $2.25M | $3.07M | $1.53M |
| Free cash flow | $6.67M | $10.5M | $9.95M | $3.76M | $6.43M |
| Depreciation and amortization | $2.77M | $3.16M | $3.58M | $3.58M | $3.26M |
| Stock-based compensation | $2.35M | $5.70M | $3.28M | $3.19M | $1.77M |
| Dividends paid | $2.34M | $2.07M | $6.94M | $1.59M | $378.0K |
| Share buybacks | $2.04M | $3.15M | $6.43M | $822.0K | $8.83M |
| Investing cash flow | -$7.31M | -$1.37M | -$2.25M | -$3.06M | -$1.53M |
| Financing cash flow | -$7.78M | -$7.60M | -$14.4M | -$2.36M | -$8.95M |
| Net change in cash | -$5.28M | $3.31M | -$4.72M | $1.42M | -$2.98M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.3% | 2.5% | 1.6% | 1.5% | 0.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.